Sanomics Revenue and Competitors
Estimated Revenue & Valuation
- Sanomics's estimated annual revenue is currently $1.7M per year.
- Sanomics's estimated revenue per employee is $77,500
Employee Data
- Sanomics has 22 Employees.
- Sanomics grew their employee count by 0% last year.
Sanomics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chairman Assistant | Reveal Email/Phone |
Sanomics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $10.2M | 131 | -2% | $312.8M | N/A |
#2 | $4.2M | 54 | N/A | N/A | N/A |
#3 | $2.2M | 57 | -28% | $179.7M | N/A |
#4 | $23.9M | 309 | -14% | N/A | N/A |
#5 | $0.9M | 12 | 0% | N/A | N/A |
#6 | $1.7M | 22 | 0% | N/A | N/A |
#7 | $19M | 245 | -14% | N/A | N/A |
#8 | $9.4M | 121 | 3% | N/A | N/A |
What Is Sanomics?
Our name "Sanomics" is derived from the word "sanguis", the Latin word for blood, and "genomics", which describes the study of genes. VISION Our principle of “Patient First†allows us to revolutionise current cancer treatments by providing safe and efficient liquid-based and tissue-based genomic tests. We aim to provide easy and convenient access to our services and help doctors decide a personalised cancer solution for patients. MISSION Based in Hong Kong, Sanomics continues expanding throughout South East Asia, with our first overseas branch opening in January of 2019 in Bangkok, Thailand. We work with health care professionals, clinics and pharmaceutical companies to develop the best care for our patients. As a pioneer in the pan-Asian genomics industry, we aspire to develop and use the latest genetic and genomic technologies to offer personalised medicine to our patients.
keywords:N/AN/A
Total Funding
22
Number of Employees
$1.7M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.6M | 22 | -21% | N/A |
#2 | $2.2M | 22 | N/A | N/A |
#3 | N/A | 22 | 0% | N/A |
#4 | $2.2M | 22 | N/A | N/A |
#5 | $3.9M | 22 | 0% | N/A |